Assay Change – BD Affirm™ VPIII Vaginosis

Effective Monday, July 22nd, Women’s Health Laboratories will begin converting our molecular testing approach for the detection of Vagionosis. We will be transitioning from the previous Access Genetics PCR based assay to the FDA-approved Becton Dickenson (BD) Affirm™ VPIII Microbial Identification System. The BD Affirm™ VPIII Assay identifies three vaginitis pathogens/pathogen groups (Candida sp, Gardnerella vaginalis, and Trichomonas vaginalis) using a single swab. The BD Affirm™ VPIII Microbial Identification Test is a DNA test that uses DNA probes that bind to the DNA of the target organisms, providing conclusive molecular evidence of the presence of the pathogen in the sample tested. The testing method has been FDA approved for over 15 years for the testing of vaginal fluid specimens from patients with clinical symptoms of vaginitis/vaginosis. Testing may be ordered for all three pathogens in one panel, or as separate tests for each individual pathogen. Results are typically available within 24 hours of receipt of the specimen at Women’s Health Laboratories.

Assay Change – illumigene® Group B Strep

Effective Tuesday, August 13th, Women’s Health Laboratories will begin converting our molecular testing approach for the detection of Group B Streptococcus. We will be transitioning from the previous Access Genetics PCR based assay to the FDA-approved illumigene® Group B Streptococcus (GBS). The illumigene® assay uses a combined bacterial culture/nucleic acid amplification approach for the detection of GBS colonization in pregnant women. This approach is the testing approach recommended by the Centers for Disease Control as well as several professional organizations. Following culture for 18-24 hours, the illumigene® GBS Assay uses loop-mediated isothermal nucleic acid amplification technology, specifically targeting the Streptococcus agalactiae genome.

Poplar Healthcare Launches New Division: Women’s Health Laboratories

Company enters OB/GYN market

(Memphis, TN) – Poplar Healthcare, a leading laboratory services company, recently launched a new division focused on the OB/GYN market, Women’s Health Laboratories.

 “We are excited to expand the markets we serve to now include the Obstetrics and Gynecology community,” stated William McDowell, CEO of Poplar Healthcare.  “With the advent of new molecular technologies that aid in the detection of sexually transmitted and pre-malignant disease, it made sense for Poplar Healthcare to leverage our existing laboratory infrastructure and managed care providership, and begin providing the latest diagnostic testing to OB/GYN physicians and their patients.”

 The Company also announced that Bradly Clark, M.D., will serve as Medical Director for Women’s Health Laboratories.  Dr. Clark received his medical degree from Howard University in Washington, D.C. and finished a residency in anatomic pathology at the National Cancer Institute in Bethesda, MD.  He then completed fellowships in both molecular diagnostics and cytopathology at the Medical College of Virginia in Richmond.  “We are thrilled to have someone with Dr. Clark’s experience and credentials lead this new division,” commented McDowell.

 “I am pleased to be part of such an exciting venture,” stated Dr. Clark. “With the combination of state-of-the art pap testing, advanced imaging systems, a broad ‘out-of-the-vial’ molecular test menu, and innovative minimally invasive histology collection options, I am confident that Women’s Health Laboratories will quickly become a leader in the rapidly advancing OB/GYN market.”

 Other key members of the Women’s Health Laboratories’ professional staff include Dr. Mark Dolz, a board-certified cytopathologist with 10 years experience, and Dr. Douglas Kingma, a board-certified hematopathologist and molecular genetic pathologist with over 10 years experience.

To find out more about Women’s Health Laboratories, visit www.womenshealthlab.com.

About Poplar Healthcare

 

Founded in 1995 and headquartered in Memphis, Poplar Healthcare is a leading laboratory services company.  Through its GI Pathology, D-PATH Dermatopathology, OncoMetrix and Women’s Health Laboratories brands, Poplar Healthcare provides specialized laboratory testing services to a nationwide client base of gastroenterologists, dermatologists, oncologists, gynecologists and their patients.  For more information on Poplar Healthcare, call 901.526.1912 or visit www.poplarhealthcare.com.

3495 Hacks Cross Rd. / Memphis, TN 38125      
Home | Site Map | Copyright © 2011. Poplar Healthcare. All Rights Reserved.